NeOnc Technologies Holdings, Inc. (NTHI)
| Market Cap | 64.50M -71.2% |
| Revenue (ttm) | 39,990 +100.0% |
| Net Income | -47.20M |
| EPS | -2.14 |
| Shares Out | 24.86M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 74,577 |
| Open | 2.710 |
| Previous Close | 2.730 |
| Day's Range | 2.530 - 2.866 |
| 52-Week Range | 2.501 - 12.090 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 17.00 (+555.11%) |
| Est. Earnings | Nov 13, 2026 |
About NTHI
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary bra... [Read more]
Financial Performance
In 2025, NTHI's revenue was $39,990, a decrease of -51.82% compared to the previous year's $83,000. Losses were -$62.15 million, 422.3% more than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for NTHI stock is "Strong Buy." The 12-month stock price target is $17.0, which is an increase of 555.11% from the latest price.
News
NeOnc among Names with 2026 Breakthroughs that Offer New Hope in the Fight Against Cancer
DENVER, Oct. 07, 2026 (GLOBE NEWSWIRE) -- ( www.247marketnews.com)-- For patients facing cancer, progress ultimately comes down to a deeply personal question: Can treatment give them more time? A ser...
NeOnc's FDA Catalyst Run Could Give NTHI a Serious Jolt
DENVER, Oct. 06, 2026 (GLOBE NEWSWIRE) -- ( 247marketnews.com) -- A fall calendar is bringing NeOnc Technologies Holdings' (NASDAQ: NTHI) investigational brain-cancer programs into focus. Anticipatio...
NeOnc Technologies announces brain cancer pipeline advances
NeOnc Technologies (NTHI) is heading toward another potentially important regulatory milestone, with the U.S. Food and Drug Administration scheduled to meet with the company on November 17, 2026, for ...
NeOnc's Powerful Brain Cancer Pipeline Advances
DALLAS, Sept. 29, 2026 (GLOBE NEWSWIRE) -- (www.InvestorsTape.com) -- NeOnc Technologies Holdings (NASDAQ: NTHI) is heading toward another potentially important regulatory milestone, with the U.S. Foo...
Powerful NeOnc Brain Cancer Pipeline Advances
NeOnc (NASDAQ: NTHI) is scheduled to meet with the FDA for an in-person End-of-Phase 1 Type B meeting covering its experimental brain-cancer drug NEO212.
NeOnc Technologies Announces FDA End of Phase 1 Meeting for NEO212
CALABASAS, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for c...
NeOnc Lands New Coverage and Roth Sees Potential 2026 Trial Catalyst
DENVER, Sept. 24, 2026 (GLOBE NEWSWIRE) -- ( 247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ: NTHI) has picked up fresh Wall Street coverage at a pivotal moment for its experimental brain-c...
NeOnc Technologies initiated with a Buy at Roth Capital
Roth Capital analyst Jonathan Aschoff initiated coverage of NeOnc Technologies (NTHI) with a Buy rating and $20 price target The firm sees the company’s NEO100 and NEO212 launching in 2029…
NeOnc's Delivery may Finally Change the Equation for Brain Cancer's Next Frontier
DENVER, Sept. 22, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com)– NeOnc Technologies Holdings (NASDAQ: NTHI) is becoming a prominent player, as brain cancer research is entering an increasingly sophisti...
NeOnc Charting New Nasal Route to Treating Brain Cancer
DENVER, Sept. 21, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – NeOnc Technologies Holdings' (NASDAQ: NTHI) NEO100 deserves attention; not just because its Phase 2a study has suddenly solved brain ca...
NeOnc Eliminates Major Dilution Risk as Clinical Story Accelerates
DENVER, Sept. 17, 2026 (GLOBE NEWSWIRE) -- ( 247marketnews.com) -- NeOnc Technologies (NASDAQ: NTHI) just removed a potentially significant overhang from its capital structure, redeeming all 6,000 ou...
NeOnc Technologies Redeems All Outstanding Series A Convertible Preferred Stock and Eliminates Related Potential Dilution
CALABASAS, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing n...
NeOnc's $629K Insider Buying Spree Follows Breakthrough Data and Now All Eyes Turn to the FDA
DENVER, Sept. 16, 2026 (GLOBE NEWSWIRE) -- ( 247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ: NTHI) executives put even more personal capital behind the company, following positive Phase 2a...
NeOnc Executives Invest Approximately $629,000 in Open-Market Stock Purchases Following Positive NEO100 Phase 2a Results
CALABASAS, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing n...
Investor Determination to Beat Cancer Puts NeOnc's Novel Therapies and Patented Platform in Focus
NeOnc's (NASDAQ:NTHI) CEO purchased another 37,000 shares of the company's common stock, following a $15 financing with healthcare-focused institutions
Insiders Continue Buying, as NeOnc Moves NEO100 Toward Its Next Regulatory Test
DENVER, Sept. 14, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ: NTHI) is sending investors a signal that is impossible to ignore.
NeOnc Raises $15 Million At Market Adding Fuel to the Strong NEO100 Data
DENVER, Sept. 09, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ:NTHI) is entering a potentially important new phase with fresh institutional capital, encouraging ...
NeOnc Technologies prices 3.57M shares at $4.20 in registered direct offering
NeOnc Technologies (NTHI) announced that it has entered into definitive securities purchase agreements with new and existing healthcare focused institutional investors for the purchase and sale of 3,5...
NeOnc Technologies Holdings, Inc. Announces Pricing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules with New and Existing Institutional Investors
CALABASAS, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) ("NeOnc" or the "Company"), a multi-Phase 2 clinical-stage biopharmaceutical company developing n...
NeOnc' Phase 2 Data Could Put Cancer on the Ropes
DENVER, Sept. 08, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – For NeOnc Technologies Holdings (NASDAQ: NTHI), the Phase 2a question has been answered.
NeOnc's Phase 2A Success Could Set the Stage for Something Much Bigger
DENVER, Aug. 28, 2026 (GLOBE NEWSWIRE) -- For NeOnc Technologies Holdings (NASDAQ: NTHI), the most important part of the NEO100 story may no longer be whether the company can produce a meaningful sign...
NeOnc's Clinical Story Is Now the Main Event
DENVER, Aug. 26, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings (NASDAQ: NTHI) has reached a point where the market conversation can move toward a much more consequential question: What happens ...
NeOnc Technologies- Talk Is Cheap, Insider Buying Isn't
DENVER, Aug. 18, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ: NTHI) has just added another potentially important element to an already potent story: its CEO, Am...
These Nasdaq Stories Are Heating Up
DENVER, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Here are today's catalysts reshaping the market narrative. NeOnc Technologies Holdings: Phase 2a Data Could Just Be the Beginning NeOnc (NASDAQ: NTHI) has pro...
NTHI's Nasdaq Advantage Takes on New Meaning After Its Breakthrough Phase 2a Results
NeOnc's (NASDAQ:NTHI) Phase 2a results for NEO100 in recurrent IDH1-mutant high-grade glioma make its Nasdaq Global Market listing way more interesting